Transition Metal Complexes as Therapeutics: A New Frontier in Combatting Neurodegenerative Disorders through Protein Aggregation Modulation

Neurodegenerative disorders (NDDs) are a class of debilitating diseases that progressively impair the protein structure and result in neurological dysfunction in the nervous system. Among these disorders, Alzheimer's disease (AD), prion diseases such as Creutzfeldt-Jakob disease (CJD), and Parkinson's disease (PD) are caused by protein misfolding and aggregation at the cellular level. In recent years, transition metal complexes have gained significant attention for their potential applications in diagnosing, imaging, and curing these NDDs. These complexes have intriguing possibilities as therapeutics due to their diverse ligand systems and chemical properties and can interact with biological systems with minimal detrimental effects. This review focuses on the recent progress in transition metal therapeutics as a new era of hope in the battle against AD, CJD, and PD by modulating protein aggregation in vitro and in vivo. It may shed revolutionary insights into unlocking new opportunities for researchers to develop metal-based drugs to combat NDDs.

A Family of [Zn6] Complexes from the Carboxylate-Bridge-Supported Assembly of [Zn2] Building Units: Synthetic, Structural, Spectroscopic, and Systematic Biological Studies

The three discrete [Zn₆] complexes [Na₃Zn₆(cpdp)₃(μ-Bz)₃(CH₃OH)₆][ZnCl₄][ZnCl₃(H₂O)]·3CH₃OH·1.5H₂O (1), [Na₃Zn₆(cpdp)₃(μ-p-OBz)₃(CH₃OH)₆]·2H₂O (2), and [Na₃Zn₆(cpdp)₃(μ-p-NO₂Bz)₃(CH₃OH)₆]Cl₃·2H₂O (3), supported by the carboxylate-based multidentate ligand N,N'-bis[2-carboxybenzomethyl]-N,N'-bis[2-pyridylmethyl]-1,3-diaminopropan-2-ol (H₃cpdp), have been successfully synthesized and fully characterized (Bz = benzoate; p-OBz = dianion of p-hydroxybenzoic acid; p-NO₂Bz = p-nitrobenzoate). The complexes have been characterized by elemental analysis, FTIR, UV-vis, NMR spectroscopy, PXRD, and thermal analysis, including single-crystal X-ray crystallography of 1 and 2. The molecular architectures of 1-3 are built from the self-assembly of their corresponding [Zn₂] units, which are interconnected to the central [Na₃(CH₃OH)₆]³⁺ core by six endogenous benzoate groups, with each linking one Zn(II) and one Na(I) ion in a μ₂:η¹:η¹-syn-anti bidentate fashion. The composition of the (cpdp^3-)₃/(Zn²⁺)₆ complexes in 1-3 has been observed to be 1:2, on the basis of the UV-vis titration and NMR spectroscopic results, which is further supported by X-ray crystallography. Systematic biological studies performed with a mice model suggested possible antidiabetic efficacy as well as anticancer activities of the complexes. When complexes 1-3 were administered intraperitoneally in mice, 1 showed a lowering in the blood glucose level, overall maintenance of the pancreatic tissue mass, restriction of DNA damage in pancreatic cells, and retention of lipid droplet (LD) frequency, whereas 2 and 3 showed hepatic tissue mass consistency by inhibiting the DNA damage in hepatic cells, prior to the exposure to a potent diabetic inducer, alloxan (ALX). Similar trends of results were observed in inhibiting the generation of reactive oxygen species (ROS) in the pancreatic and hepatic cells, as examined by spectrofluorometric methods. Thus, 1 seems to be a better compound for overall diabetic management and control, whereas 2 and 3 seem to be promising compounds for designing chemopreventive drugs against hepatic carcinoma.

Synthesis of (3-nitro-2-oxo-benzaldehyde thiosemicarbazonato)-zinc(II) complexes: the position of nitro group in phenyl ring alters antimicrobial activity against K. pneumoniae 1, S. typhimurium 2, MRSA and C. albicans

The basic purpose of this investigation was to explore the effect on antimicrobial activity of a nitro group at an ortho- versus para-position in the 2-hydroxy-phenyl ring of nitro-salicylaldehyde-N-substituted thiosemicarbazone (X-NO2-stscH2-N1HR, X = 3 or 5; stsc-stands for salicyladehyde thiosemicarbazone) complexes with zinc. Reactions of zinc(ii) acetate with 3-nitro-salicylaldehyde-N-substituted thiosemicarbazones (3-NO2-stscH2-N1HR) and 2,2-bipyridine, or 1,10-phenanthroline as co-ligands, yielded complexes of stoichiometry, [Zn(3-NO2-stsc-N1HR)(N,N-L)] {L, R: bipy, H, 1; Me, 2; Et, 3; Ph, 4; phen, H, 5; Me, 6; Et, 7; Ph, 8}. The thio-ligands coordinate to the metal as dianions (deprotonation of -OH and -N2H moieties) through O, N3 and S donor atoms in distorted trigonal bipyramid geometry (4, 5, 7: τ = 0.718-0.576) or in distorted square pyramid geometry (8: τ = 0.349). ESI-mass spectrometry supported the formation of molecular ion peaks. Complexes displayed fluorescence with λmax = 438-473 nm. It was found that these five-coordinated [Zn(3-NO2-stsc-N1HR)(N,N-L)] complexes showed high antimicrobial activity against methicillin resistant S. aureus (MRSA), Klebsiella pneumoniae 1, Salmonella typhimurium 2 and C. albicans vis-à-vis that of 5-NO2-stscH2-N1HR zinc complexes reported earlier. However, in comparison, the antimicrobial activity of 5-nitro complexes against S. aureus was high relative to 3-nitro complexes in the present case.

Probing 4-(diethylamino)-salicylaldehyde-based thiosemicarbazones as multi-target directed ligands against cholinesterases, carbonic anhydrases and α-glycosidase enzymes

With the fading of 'one drug-one target' approach, Multi-Target-Directed Ligands (MTDL) has become a central idea in modern Medicinal Chemistry. The present study aimed to design, develop and characterize a novel series of 4-(Diethylamino)-salicylaldehyde based thiosemicarbazones (3a-p) and evaluates their biological activity against cholinesterase, carbonic anhydrases and α-glycosidase enzymes. The hCA I isoform was inhibited by these novel 4-(diethylamino)-salicylaldehyde-based thiosemicarbazones (3a-p) in low nanomolar levels, the Ki of which differed between 407.73 ± 43.71 and 1104.11 ± 80.66 nM. Against the physiologically dominant isoform hCA II, the novel compounds demonstrated K_is varying from 323.04 ± 56.88 to 991.62 ± 77.26 nM. Also, these novel 4-(diethylamino)-salicylaldehyde based thiosemicarbazones (3a-p) effectively inhibited AChE, with Ki values in the range of 121.74 ± 23.52 to 548.63 ± 73.74 nM. For BChE, Ki values were obtained with in the range of 132.85 ± 12.53 to 618.53 ± 74.23 nM. For α-glycosidase, the most effective Ki values of 3b, 3k, and 3g were with Ki values of 77.85 ± 10.64, 96.15 ± 9.64, and 124.95 ± 11.44 nM, respectively. We have identified inhibition mechanism of 3b, 3g, 3k, and 3n on α-glycosidase AChE, hCA I, hCA II, and BChE enzyme activities. Hydrazine-1-carbothioamide and hydroxybenzylidene moieties of compounds play an important role in the inhibition of AChE, hCA I, and hCA II enzymes. Hydroxybenzylidene moieties are critical for inhibition of both BChE and α-glycosidase enzymes. The findings of in vitro and in silico evaluations indicate 4-(diethylamino)-salicylaldehyde-based thiosemicarbazone scaffold to be a promising hit for drug development for multifactorial diseases like Alzheimer's disease.

Synthesis of 2-acetylpyridine-N-substituted thiosemicarbazonates of copper(ii) with high antimicrobial activity against methicillin resistant S. aureus, K. pneumoniae 1 and C. albicans

The basic interest in the present study pertains to developing metal based antimicrobial agents, as several microorganisms have built resistance to the conventional drugs.

Synthesis, structures, antimicrobial activity and biosafety evaluation of pyridine-2-formaldehyde-N-susbtituted-thiosemicarbazonates of copper(ii)

Copper(ii) complexes with pyridine based thiosemicarbazones have shown high antimicrobial potential against different microbial strains, and were found to be biosafe with several complexes displaying high cell viability (90–98%).

Synthesis, structures, and ESI-mass studies of silver(I) derivatives of imidazolidine-2-thiones: Antimicrobial potential and biosafety evaluation

The basic objective of this investigation is to explore potential metallo-organic antimicrobial agents based on silver-heterocyclic-2-thiones. In this respect, a series of silver(I) halide complexes with imidazolidine-2-thiones (L-NR, R=H, Me, Et, Prⁿ, Buⁿ, Ph), namely, mononuclear [AgX(L-NR)(PPh₃)₂] (X, R: Cl, Bu, 1; Br, Ph, 7); [AgX(L-NR)₃] (Br, Bu, 5; Br, Prⁿ, 8) and halogen bridged dinuclear [Ag₂(μ-X)₂(L-NR)₂(PPh₃)₂] (Cl, Buⁿ, 2; Cl, Ph, 3; Cl, Prⁿ, 4; Br, Ph, 6) have been synthesized and characterized using modern techniques. The thio-ligands are terminally S-bonded in all the complexes. The in vitro antimicrobial potential and biosafety evaluation of the above complexes as well as that of previously reported analogous silver complexes has been studied against Gram positive bacteria, namely, Staphylococcus aureus (MTCC 740) and Methicillin resistant Staphylococcus aureus (MRSA), Gram negative bacteria Klebsiella pneumoniae (MTCC 109), Salmonella typhimurium (MTCC 98) and a yeast Candida albicans (MTCC 227). Most of the complexes tested have shown significant antimicrobial activity with low values of minimum inhibitory concentration (MIC). Significantly, the activity against MRSA is an important outcome of this investigation. Among complexes tested for their cytotoxicity using MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay, some complexes showed low cellular toxicity with high percent cell viability. A dinuclear complex [Ag₂(μ-Cl)₂(L-NPh)₂(PPh₃)₂] 3 with 93.3% cell viability emerges the most important candidate for further investigations.

Variable coordination and C–S bond cleavage activity of N-substituted imidazolidine-2-thiones towards copper: synthesis, spectroscopy, structures, ESI-mass and antimicrobial studies

N-substituted imidazoldine-2-thiones with copper(i) halides have shown variable nuclearity, C–S bond cleavage, antimicrobial activity and non-toxicity in some cases to living cells.